Karolinska Institutet and the pharmaceutical company Janssen collaborate for treatments of the future
Collaborations between business and academia are important for generating new knowledge and creating solutions that benefit society. Within life science, we see a development where companies are seeking to be part of environments with different types of actors and examples of well-functioning cooperation.
Data-driven research provides new medical treatments
The report "The data revolution in life science and healthcare" shows how large amounts of research data give us a completely new understanding of human biology and how tailor-made treatments for various diseases are developed. The report, written by Stockholm Science City Foundation, also highlights the importance of trust between individuals, researchers, authorities, and companies, as well as what has prepared the progress.
Closer cooperation with Oslo and Copenhagen
In February 2023, the Foundation signed an MoU (Memorandum of understanding) with Oslo Science City and Copenhagen Science City. This gives us the opportunity for deeper collaboration and knowledge exchange.
Testa Center simplifies the journey from research to commercialization
An innovation hub for biological production to enable the verification of biological, technical, and digital innovations in an authentic production environment. Testa Center is a joint venture between the Swedish government and Cytiva to promote growth in life science.
Patenting AI and Blockchain innovations within the life science field
Applying artificial intelligence, machine learning, and blockchain in life science is becoming increasingly common.
Medal for outstanding contributions to society
With pride and joy, we announce that Cecilia Schelin Seidegård, chairman of the board at Stockholm Science City, has been awarded the medal "For outstanding contributions to society" by the King.
The new Swedish biobank act strengthens cooperation within life science in Sweden
A new biobank act comes into force on July 1, 2023. Mark Divers is the director of KI Biobank, for pre-analytical handling, storage, and distribution of human biological samples for research at Karolinska Institutet. Here he explains why a biobank law is needed, what changes the new act brings, and how it strengthens Sweden as a life science nation.
Biobanks Are Vital for Healthcare - Today and Tomorrow
Biobanks are essential for good and equal care, clinical research, and Sweden's competitiveness in Life Science. With the help of biobank samples, it is possible to prevent or alleviate the effects of public diseases, epidemics, and pandemics, which we clearly experienced during covid-19. Collaboration between all stakeholders in Life Science is key.